Skip to main content

Theseus Pharmaceuticals Inc(THRX-Q)
NASDAQ

Today's Change
Delayed Last Update

Theseus Pharmaceuticals Announces Business Highlights and Reports First Quarter 2023 Financial Results

PR Newswire - Thu May 11, 2023

-- THE-630 initial dose escalation data to be presented at investor event on May 25, 2023, with additional dose escalation data expected in Q4 2023 --

-- IND submission for THE-349 in EGFR-mutant NSCLC expected in Q4 2023; development candidate nomination for BCR-ABL program in CML and Ph+ ALL expected by early 2024 --

Read more at prnewswire.com

Provided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.

More from The Globe